Multinational phase 2 trial of tucatinib plus trastuzumab for previously treated HER2-positive metastatic biliary tract cancer
Dr. Yoshiaki Nakamura
SGNTUC-019 is a multinational phase 2 basket study evaluating the combination of tucatinib and trastuzumab for HER2-altered solid tumors. In the cohort of previously treated HER2-positive metastatic biliary tract cancer (mBTC) patients, the combination had clinical activity with a confirmed objective response rate of 46.7% and a disease control rate of 76.6%. The median duration of response was 6.0 months. The twelve-months overall survival rate was 53.6%. The combination was well tolerated and safe, with a low rate of treatment-related serious and high-grade adverse events and treatment discontinuations. The authors conclude that HER2 represents a viable target for biliary tract cancers.
